CG Oncology Price Target Maintained With a $75.00/Share by Cantor Fitzgerald

CG Oncology Price Target Maintained With a $75.00/Share by Cantor Fitzgerald

Dow Jones00:12

Cantor Fitzgerald: The CG Oncology (CGON.US) rating was confirmed and adjusted from an increase to an increase in holdings rating, with a target price of $75.00.

Cantor Fitzgerald: The CG Oncology (CGON.US) rating was confirmed and adjusted from an increase to an increase in holdings rating, with a target price of $75.00.

Zhitong Finance00:04

Cantor Fitzgerald Reiterates Overweight on CG Oncology, Maintains $75 Price Target

Cantor Fitzgerald analyst Josh Schimmer reiterates CG Oncology (NASDAQ:CGON) with a Overweight and maintains $75 price target.

Benzinga00:02

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

IRVINE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing

GlobeNewswireApr 26 20:00

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination With Pembrolizumab at ASCO 2024

IRVINE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing

GlobeNewswireApr 24 22:00

Buy Rating Affirmed for CG Oncology Amidst Bladder Cancer Treatment Landscape and BCG Shortage

TipRanksApr 23 20:25